Abbott Laboratories (ABT)
Best Dividend Aristocrats For October 2025
Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristocrats already raising payouts in 2025 at an average rate of 5.19%, nearing last year's pace. 22 Dividend Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
Here's Why Abbott (ABT) Fell More Than Broader Market
In the closing of the recent trading day, Abbott (ABT) stood at $133.89, denoting a -1.47% move from the preceding trading day.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Gains in Nutrition With Adult Segment Leading Growth
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter Abbott's long-term moat. As a dividend aristocrat, its fundamental and valuation risks are better gauged by its dividend payouts than accounting EPS.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
3 Dividend Growth Stocks That Will Deliver Meaty Returns After 5 Years
Sufficient earnings growth to continually increase dividends at a comfortably low payout ratio that also accommodates expansion capex is an excellent signal for strong upside potential.
